Obesity clinical trials, in English

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.

NCT03025074 · Official ClinicalTrials.gov record · State University of New York at Buffalo

Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).

NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes.

NCT05000996 · Official ClinicalTrials.gov record · Vanderbilt University Medical Center

The present watch-and-measure (no experimental treatment required) cross-sectional study is aimed to assess: the hidden hypercortisolism (HidHyCo) prevalence in a sample of Type 2 diabetes (T2D) patients and the clinical characteristics more frequently associated with the HidHyCo presence and the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.

NCT05759637 · Official ClinicalTrials.gov record · Istituto Auxologico Italiano

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

NCT05819853 · Official ClinicalTrials.gov record · University of Colorado, Denver

Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". Long COVID can affects any type of patient and has polymorphic and fluctuating symptoms over time.

NCT05851859 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de la Réunion

The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, body-mass index (BMI), and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.

NCT05950282 · Official ClinicalTrials.gov record · Ali Chappell

Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions.

NCT05972564 · Official ClinicalTrials.gov record · Vanderbilt University Medical Center

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

NCT06132477 · Official ClinicalTrials.gov record · University of Missouri-Columbia

A randomly assigned, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.

NCT06133101 · Official ClinicalTrials.gov record · Marialena Mouzaki

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to measure the safety and how well it works of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs.

NCT06143956 · Official ClinicalTrials.gov record · Eli Lilly and Company

This chronic study aims at assessing whether the effects of a personalized, plant-based diet rich in (poly)phenols on cardiometabolic health depend on the capability to metabolize dietary (poly)phenols, creating predictive models able to explain, at individual level, the cardiometabolic response. This study presents an watch-and-measure (no experimental treatment required) part, for targeted recruitment and volunteers characterization, and an experimental part for the dietary and deep phenotyping.

NCT06347094 · Official ClinicalTrials.gov record · University of Parma

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. this study wants to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

NCT06632444 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD.

NCT06671886 · Official ClinicalTrials.gov record · VA Office of Research and Development

The study will assign participants to take either the medication, empagliflozin or a dummy treatment (placebo) for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

NCT06745063 · Official ClinicalTrials.gov record · VA Office of Research and Development

This study wants to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity.

NCT06842186 · Official ClinicalTrials.gov record · Wave Life Sciences USA, Inc.

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.

NCT06857942 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with dummy treatment (placebo) in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

NCT06897475 · Official ClinicalTrials.gov record · Eli Lilly and Company

This clinical trial aims to determinate whether a structured exercise program, supported by telerehabilitation, can help individuals with severe obesity who are going to undergo bariatric surgery. The main objective of this study is whether a structured exercise program, including both supervised and home-based workouts, leads to greater body fat loss and improved strength compared to usual care.

NCT06934681 · Official ClinicalTrials.gov record · Instituto de Investigacion Sanitaria La Fe

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and dummy treatment (placebo), leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

NCT06937086 · Official ClinicalTrials.gov record · Eli Lilly and Company

The main purpose of this study is to measure the how well it works and safety of mirikizumab and dummy treatment (placebo) compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

NCT06937099 · Official ClinicalTrials.gov record · Eli Lilly and Company

Hispanic adolescents are disproportionately burdened by type 2 diabetes (T2D). Social determinants of health (SDoH) serve as barriers to behavior change and participation in disease prevention efforts, especially among vulnerable adolescents.

NCT06943001 · Official ClinicalTrials.gov record · Baylor College of Medicine

The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults.

NCT06949280 · Official ClinicalTrials.gov record · Rutgers, The State University of New Jersey

Are disproportionately burdened by type 2 diabetes (T2D) compared to non-Hispanic white youth (0.079% vs. 0.017%) contributing to higher rates of T2D-related vascular complications, cardiovascular disease, and mortality, among this population.

NCT06959901 · Official ClinicalTrials.gov record · Baylor College of Medicine

Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

NCT07058155 · Official ClinicalTrials.gov record · The Cleveland Clinic

LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study.

NCT07065552 · Official ClinicalTrials.gov record · UNC Lineberger Comprehensive Cancer Center

This 12-week, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight and obese adults aged 18 to 40. Seventy you would be randomly assigned to receive either Lab4P or a dummy treatment (placebo).

NCT07073781 · Official ClinicalTrials.gov record · Leeds Beckett University

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1.

NCT07107334 · Official ClinicalTrials.gov record · University of Florida

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.

NCT07111494 · Official ClinicalTrials.gov record · Medical College of Wisconsin

This study wants to determine the most effective family-centered intervention (FCI) for weight loss and obesity prevention in Hispanic families. FCI is a type of program that involves family (such as parents and caregivers) supporting their children to promote healthy habits.

NCT07144800 · Official ClinicalTrials.gov record · Memorial Sloan Kettering Cancer Center

The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities. Normal puberty onset and progression is dependent on normal hypothalamic-pituitary-gonadal (HPG) axis which is affected by whole body metabolism.

NCT07169136 · Official ClinicalTrials.gov record · Nemours Children's Clinic

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.

NCT07207148 · Official ClinicalTrials.gov record · Northwestern University

This study wants to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.

NCT07218445 · Official ClinicalTrials.gov record · Mayo Clinic

This randomly assigned, sham-controlled trial evaluates the how well it works and safety of ERCG plus optimized lifestyle intervention compared with sham procedure plus optimized lifestyle intervention in Chinese adults with overweight accompanied by at least one metabolic comorbidity or with mild-to-moderate obesity. The co-primary outcomes are percentage total weight loss (%TWL) at 12 weeks and the clinical response rate at 12 weeks, defined as the proportion of participants achieving %TWL ≥5%.

NCT07237750 · Official ClinicalTrials.gov record · Liu Yan

The prevalence of Vitamin D deficiency is significantly higher in adults with overweight/obesity compared to those with normal body mass index (body-mass index (BMI)). The "entrapment" of Vitamin D in adipose tissue due to impaired lipolytic stimulation and/or adipose tissue dysfunction has been proposed as the driving mechanism.

NCT07300332 · Official ClinicalTrials.gov record · University of Thessaly

This study will look at whether a reduced-calorie Mediterranean-style eating plan, together with a synbiotic supplement, can improve health measures and quality of life in women who have polycystic ovary syndrome (PCOS) and are overweight or have obesity. you would be assigned by chance (like flipping a coin) to receive either the synbiotic supplement or a dummy treatment (placebo) (a look-alike product with no active ingredients).

NCT07342946 · Official ClinicalTrials.gov record · Atlas University

This study wants to assess the how well it works and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with dummy treatment (placebo) for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

NCT07351045 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study wants to assess the how well it works and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with dummy treatment (placebo) for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

NCT07351058 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain.

NCT07353931 · Official ClinicalTrials.gov record · Eli Lilly and Company

The purpose of the studies is to measure the how well it works and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.

NCT07369011 · Official ClinicalTrials.gov record · Eli Lilly and Company

EGO-Trial is the first multicenter study in France which aims to measure the how well it works of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, how well it works, and variability of ESG practices across institutions The project is expected to generate robust, multicentric clinical evidence on the safety and how well it works of ESG in patients with obesity within the French healthcare context.

NCT07449520 · Official ClinicalTrials.gov record · IHU Strasbourg

This study wants to: * measure the safety, tolerability, how well it works, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 in patients with obesity * measure the safety, tolerability, how well it works, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

NCT07463846 · Official ClinicalTrials.gov record · Alnylam Pharmaceuticals

Phase 2, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus dummy treatment (placebo) in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.

NCT07467447 · Official ClinicalTrials.gov record · Hudson Biotech

The goal of this clinical trial is to assess whether added on top of your current treatment dental cleaning can enhance the effects of semaglutide in children with obesity. The main question\[s\] it aims to answer \[is/are\]: if dental cleaning will improve both oral health and metabolic outcomes beyond the effects of semaglutide alone.

NCT07478653 · Official ClinicalTrials.gov record · Oelisoa Andriankaja

The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

NCT07511205 · Official ClinicalTrials.gov record · AstraZeneca

This study is being done to look at the how well it works and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.

NCT07571109 · Official ClinicalTrials.gov record · Novo Nordisk A/S

The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can help adults with obesity without diabetes stay on treatment longer, while maintaining weight-loss effectiveness. The main questions it aims to answer are: * Does flexible, symptom-guided titration increase time on treatment (delay treatment discontinuation) compared with standard per-label titration over 76 weeks?

NCT07574723 · Official ClinicalTrials.gov record · Dasman Diabetes Institute

The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.

NCT07587710 · Official ClinicalTrials.gov record · Novo Nordisk A/S

The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are: * Will excessive fat be associated with brain abnormalities on MRI measures?

NCT07592546 · Official ClinicalTrials.gov record · Alain Dagher

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight.

NCT07595549 · Official ClinicalTrials.gov record · Pfizer

Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine and metabolic disorder among women of reproductive age. It is characterized by oligo-ovulation or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology.

NCT07616037 · Official ClinicalTrials.gov record · Shanghai Zhongshan Hospital

Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.

NCT07651319 · Official ClinicalTrials.gov record · The Methodist Hospital Research Institute

This study wants to assess the how well it works and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.

NCT07670416 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to dummy treatment (placebo) and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

NCT07685808 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

This multicenter randomly assigned controlled trial will evaluate whether an AI-assisted intensive lifestyle intervention can improve weight and glycemic management in adults with obesity and newly diagnosed type 2 diabetes, compared with tirzepatide treatment and standard lifestyle management. Eligible you would be adults aged 18 to 65 years with a body mass index of 28 to less than 40 kg/m² and newly diagnosed type 2 diabetes who have not used glucose-lowering medications in the past 3 months.

NCT07697391 · Official ClinicalTrials.gov record · The First Affiliated Hospital of Anhui Medical University

This trial will test the effectiveness of a weight loss maintenance intervention designed to help participants respond more adaptively to weight regain. you would be randomly assigned to one of two conditions.

NCT07708064 · Official ClinicalTrials.gov record · ORI Community and Evaluation Services

The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, how well it works and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.

NCT07743983 · Official ClinicalTrials.gov record · BrightGene Bio-Medical Technology Co., Ltd.

This study is a 6-month, two-arm, RCT which will measure the effectiveness and safety of semaglutide in adolescents aged 12-18 years with autism spectrum disorder (ASD) and obesity. The primary outcome is change in body mass index (body-mass index (BMI), kg/m²) from baseline to Month 6.

NCT07770152 · Official ClinicalTrials.gov record · Children's Hospital Medical Center, Cincinnati

Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction. Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain.

NCT07770711 · Official ClinicalTrials.gov record · Dicle University

This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus dummy treatment (placebo) in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

NCT07772960 · Official ClinicalTrials.gov record · Yale University

This study wants to measure the how well it works and safety of elecoglipron compared with dummy treatment (placebo) adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

NCT07775404 · Official ClinicalTrials.gov record · AstraZeneca

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. how well it works of AZD6234 will be compared to dummy treatment (placebo) in percent body weight change from baseline at 68 weeks of treatment.

NCT07776509 · Official ClinicalTrials.gov record · AstraZeneca

Incretin-based pharmacotherapies induce significant weight loss and represent a paradigm shift in obesity treatment. However, particularly fast weight loss may be accompanied by a significant loss of muscle mass, which is associated with a reduced metabolic rate at rest and during physical activity, increased insulin resistance, limited mobility, and potential long-term adverse effects.

NCT07777575 · Official ClinicalTrials.gov record · Technical University of Munich

This study wants to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with dummy treatment (placebo) in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.

NCT07783802 · Official ClinicalTrials.gov record · Eli Lilly and Company

Asthma is a heterogeneous disease characterized by chronic airway inflammation, leading to variable airflow obstruction, bronchial hyperresponsiveness, excessive mucus secretion, and, consequently, structural airway remodeling. Asthma is defined by the presence of symptoms such as wheezing, dyspnea, chest tightness, and cough, with variable intensity and frequency.

NCT07786870 · Official ClinicalTrials.gov record · Medical University of Warsaw

The goal of this feasibility randomly assigned controlled trial is to assess the feasibility, acceptability, and demand, as well as preliminary effects of an evidence-based Intuitive Eating (IE) intervention among pregnant women who have obesity. The main research questions are: RQ1: What is the feasibility (acceptability and demand) of implementing an Intuitive Eating Intervention among pregnant and postpartum women?

NCT07792837 · Official ClinicalTrials.gov record · San Diego State University

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to measure the how well it works, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in the study will last about 104 weeks.

NCT07817875 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who use a breathing machine (positive airway pressure \[PAP\] machine).

NCT07823608 · Official ClinicalTrials.gov record · Pfizer

This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and helps support weight loss.

NCT07830329 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

Researchers want to understand what happens to muscle and fat in the body after adults with obesity and/or type 2 diabetes start taking a GLP-1 receptor agonist medication (GLP-1RA), a type of drug already approved and commonly prescribed for weight loss and blood sugar control. No experimental medication will be given.

NCT07835360 · Official ClinicalTrials.gov record · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

This randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to measure the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection

NCT07842640 · Official ClinicalTrials.gov record · Ascletis Pharma (China) Co., Limited

This study will measure the how well it works and safety of petrelintide compared with dummy treatment (placebo), in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).

NCT07843485 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study wants to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.

NCT07845500 · Official ClinicalTrials.gov record · Pfizer

This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD.

NCT07854782 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals

The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

NCT07855133 · Official ClinicalTrials.gov record · Novo Nordisk A/S

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity.

NCT07858864 · Official ClinicalTrials.gov record · Istanbul Saglik Bilimleri University

The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

NCT07866066 · Official ClinicalTrials.gov record · Amgen

This single-center randomly assigned comparative study is designed to compare the effectiveness of tirzepatide and transcutaneous low-frequency auricular vagus nerve stimulation in adults with class I obesity and without chronic non-communicable diseases. The study focuses on changes in body weight, anthropometric indices, epicardial and visceral adipose tissue, body composition, behavioral factors, skeletal muscle characteristics, and cardiac structure and function.

NCT07866183 · Official ClinicalTrials.gov record · National Medical Research Center for Therapy and Preventive Medicine

The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get tirzepatide and zenagamtide.

NCT07868354 · Official ClinicalTrials.gov record · Novo Nordisk A/S

The goal of this clinical trial is to investigate how GLP-1 receptor analogs, such as semaglutide (Wegovy®), influence processes that determine eating behavior, binge eating, and weight regulation via the gut-brain axis. The main question it aims to answer is: to identify for whom semaglutide works best.

NCT07870538 · Official ClinicalTrials.gov record · Universitaire Ziekenhuizen KU Leuven

The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.

NCT07871409 · Official ClinicalTrials.gov record · Amgen

The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor mental health, and decreased life expectancy.

NCT07872904 · Official ClinicalTrials.gov record · Signe Torekov

Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other medical conditions.

NCT07874633 · Official ClinicalTrials.gov record · Pfizer

This is a prospective, single-arm, open-label feasibility trial conducted at the MD Anderson Sarcoma Center and Cardio-Oncology Clinic. The study will enroll young adults (18-39 years) with soft tissue or bone sarcoma who are overweight (body-mass index (BMI) 25-29.9 kg/m² with ≥1 cardiovascular risk factor) or obese (body-mass index (BMI) ≥30 kg/m²), have completed Dox-based chemotherapy (≥300 mg/m²) approximately three months prior to enrollment, and have preserved LVEF (≥50%) preenrollment.

NCT07874828 · Official ClinicalTrials.gov record · M.D. Anderson Cancer Center

This study wants to investigate the how well it works and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.

NCT07881458 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who are not using a breathing machine (positive airway pressure \[PAP\] machine).

NCT07881757 · Official ClinicalTrials.gov record · Pfizer

The goal of this 24 week double-blinded, randomly assigned, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity. The main question to answer is: What effect does Semaglutide have on body composition in adults with type 1 diabetes and overweight/obesity compared to a dummy treatment (placebo)?

NCT07891156 · Official ClinicalTrials.gov record · McGill University Health Centre/Research Institute of the McGill University Health Centre

The purpose of this clinical study is to determine if the study medicine NNC9836-0001 is safe and tolerable in healthy participants with overweight or obesity or who have type 2 diabetes (T2D). Participants will either get the study medicine NNC9836-0001 or dummy treatment (placebo).

NCT07896109 · Official ClinicalTrials.gov record · Novo Nordisk A/S

This study will investigate brown adipose tissue-related physiological responses in women with polycystic ovary syndrome (PCOS). Women with PCOS who have normal body mass index, women with PCOS who are overweight or have obesity, and healthy women will be compared.

NCT07896642 · Official ClinicalTrials.gov record · Istanbul Health and Technology University

The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes. The main questions it aims to answer are: \- Does tirzepatide have a greater effect on energy expenditure or energy extraction than semaglutide?

NCT07900074 · Official ClinicalTrials.gov record · McMaster University

This watch-and-measure (no experimental treatment required) study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach. Adults starting GLP-1 medications as part of their usual care will be followed for 24 months.

NCT07901777 · Official ClinicalTrials.gov record · Yuzuncu Yil University

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to dummy treatment (placebo) on knee pain, physical function, and body weight.

NCT07915609 · Official ClinicalTrials.gov record · Pfizer

Heart failure with preserved ejection fraction (HFpEF) is characterized by typical symptoms of heart failure, structural and functional cardiac abnormalities, and elevated serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), despite preserved left ventricular ejection fraction. Typical symptoms of HFpEF include reduced exercise tolerance, exertional dyspnea, paroxysmal nocturnal dyspnea, and orthopnea.

NCT07918209 · Official ClinicalTrials.gov record · American Heart of Poland

The aim of the study is to assess the influence of continuous glucose monitoring (CGM) systems on metabolic control and quality of life in people with type 2 diabetes and overweight/obesity who are not treated with insulin. Additionally, the study aims to assess the association between metabolic control of diabetes and markers of early cardiovascular disease, taking into account the impact of CGM use.

NCT07919236 · Official ClinicalTrials.gov record · Medical University of Bialystok

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to dummy treatment (placebo) on knee pain, physical function, and body weight.

NCT07919678 · Official ClinicalTrials.gov record · Pfizer

This study will examine changes in ankle muscle activity and functional performance following whole-body vibration training in women with obesity, with and without type 2 diabetes. It will also compare the responses to training between these two groups.

NCT07924436 · Official ClinicalTrials.gov record · Pamukkale University

This prospective watch-and-measure (no experimental treatment required) study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included.

NCT07924618 · Official ClinicalTrials.gov record · Istanbul University

Obesity and exposure to fine particulate matter (particles of aerodynamic diameter less than 2.5 µm, PM2.5) air pollution are established risk factors for cardiovascular (CV) morbidity and mortality. This proposed pilot project seeks to assess interactions between PM2.5 exposure, obesity, CV health, and dietary antioxidant in subjects with obesity.

NCT07924839 · Official ClinicalTrials.gov record · Michigan State University

The goal of this clinical trial is to explore the weight loss effect of Amway "BODY TRIMMER" on study participants with abdominal obesity. The main questions it aim to answer is: Does Amway "BODY TRIMMER" reduce the weight of Study participants?

NCT07924956 · Official ClinicalTrials.gov record · Amway (China) R&D Center

This study aims to find the suitable dose of remimazolam combined with alfentanil for sedation during gastroscopy in obese patients. We will use a biased coin up-and-down sequential design to identify the 90% effective dose (ED90).

NCT07925684 · Official ClinicalTrials.gov record · Jianbo Wu

The goal of this watch-and-measure (no experimental treatment required) study is to learn how treatment with incretins, such as semaglutide and tirzepatide, affects muscle mass, muscle strength, and physical function in people with overweight or obesity. The main questions this study aims to answer are: * What is the composition of weight loss during incretin treatment?

NCT07929831 · Official ClinicalTrials.gov record · Radboud University Medical Center